Docetaxel plus ramucirumab (DR) versus docetaxel plus placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.

被引：0
|
作者：
Hosomi, Yukio
Yoh, Kiyotaka
Kasahara, Kazuo
Yamada, Kazuhiko
Takahashi, Toshiaki
Tanaka, Kaoru
Hida, Toyoaki
Yoshioka, Hiroshige
Kato, Terufumi
Takeda, Koji
Nishio, Makoto
Sakai, Hiroshi
Maemondo, Makoto
Takenoyama, Mitsuhiro
Nokihara, Hiroshi
Tatsumi, Masumi
Nakamura, Takashi
Enatsu, Sotaro
Tamura, Tomohide
Nakagawa, Kazuhiko
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[3] Kanazawa Univ, Grad Sch Med Sci, Dept Resp Med, Cellular Transplantat Biol, Kanazawa, Ishikawa, Japan
[4] Kurume Univ, Sch Med, Kurume, Fukuoka 830, Japan
[5] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[6] Kiniki Univ, Fac Med, Osaka, Japan
[7] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[8] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
[9] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan
[10] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[11] Japanese Fdn Canc Res, Tokyo, Japan
[12] Saitama Canc Ctr, Saitama, Japan
[13] Miyagi Canc Ctr, Sendai, Miyagi, Japan
[14] Kyushu Canc Ctr, Natl Hosp Org, Fukuoka, Japan
[15] Natl Canc Ctr, Tokyo, Japan
[16] Eli Lilly Japan, Kobe, Hyogo, Japan
[17] Lilly Res Labs Japan, Kobe, Hyogo, Japan
[18] St Lukes Int Hosp, Tokyo, Japan
[19] Kinki Univ, Fac Med, Osakasayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8054
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial
    Georgoulias, V
    Ardavanis, A
    Agelidou, A
    Agelidou, M
    Chandrinos, V
    Tsaroucha, E
    Toumbis, M
    Kouroussis, C
    Syrigos, K
    Polyzos, A
    Samaras, N
    Papakotoulas, P
    Christofilakis, C
    Ziras, N
    Alegakis, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2602 - 2609
  • [32] Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)
    Herbst, Roy S.
    Ansari, Rafat H.
    Gorbunova, V
    Manikhas, G.
    Mansoor, N. Boyd
    Thomas, E.
    Azzoli, Christopher G.
    Robert, Francisco
    Itri, Loretta M.
    Chapman, Robert
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S335 - S335
  • [33] Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
    de Boer, Richard H.
    Arrieta, Oscar
    Yang, Chih-Hsin
    Gottfried, Maya
    Chan, Valorie
    Raats, Johann
    de Marinis, Filippo
    Abratt, Raymond P.
    Wolf, Juergen
    Blackhall, Fiona H.
    Langmuir, Peter
    Milenkova, Tsveta
    Read, Jessica
    Vansteenkiste, Johan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1067 - 1074
  • [34] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial
    Georgoulias, V.
    Ardavanis, A.
    Tsiafaki, X.
    Agelidou, A.
    Syrigos, K.
    Polyzos, A.
    Kakolyris, S.
    Kouroussis, Ch
    Androulakis, N.
    Chatzidaki, D.
    ANNALS OF ONCOLOGY, 2004, 15 : 169 - 169
  • [35] A PHASE II STUDY OF DOCETAXEL MONOTHERAPY IN SECOND-LINE TREATMENT IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Reza, M. S.
    Hai, M. A.
    Chowdhury, Q.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 120
  • [36] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Valerie Israel
    Scott T. Tagawa
    Terry Snyder
    Susan Jeffers
    Derek Raghavan
    Investigational New Drugs, 2004, 22 : 291 - 297
  • [37] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Israel, V
    Tagawa, ST
    Snyder, T
    Jeffers, S
    Raghavan, D
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 291 - 297
  • [38] A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC).
    Kouroussis, C
    Syrigos, K
    Potamianou, A
    Ziras, N
    Ziotopoulos, P
    Stergiou, J
    Ginopoulos, P
    Tselepatiotis, E
    Biozionelou, V
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 681S - 681S
  • [39] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [40] Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
    Rugo, Hope S.
    Stopeck, Alison T.
    Joy, Anil A.
    Chan, Stephen
    Verma, Shailendra
    Lluch, Anna
    Liau, Katherine F.
    Kim, Sinil
    Bycott, Paul
    Rosbrook, Brad
    Bair, Angel H.
    Soulieres, Denis
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2459 - 2465
12345